The PEAD projected a bearish outlook for NASDAQ:GILD after a negative under reaction following its earnings release placing the stock in drift D with an expected accuracy of 72.73%.
XABCD, ABC patterns at play. Confirmation via eMA, candlestick pattern. Here we go.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Confirmation level, where relevant, is a pink dotted, finite line. Fibonacci goals, it is...
Long-term weekly high - Liquidity PURGED.
We've seen a short-term low broken with bearish displacement candle; leaving a FVG (SIBI) in its wake.
We've seen price break down and trade back into the bottom of the bearish breaker twice, which is being highly respected with candle wicks and bodies.
Each touch we see price react and move away from the area...
The PEAD projected a Bullish outlook for $GILD after a Positive over reaction following its earnings release placing the stock in drift B with an expected accuracy of 50%.
Gilead offers a very nice setup here, upside as per the chart. You can expect it to do well during January if it holds over $85.43 for the most part, might consolidate again after February the 1st.
Best of luck if taking this one.
Cheers,
Ivan Labrie.
GILD has been on a monster run, up one day, up the next and failed to pierce through the triple top. Bio pharma stocks are always difficult both short and long, every time I trade one it's always the last time. LOL $71 gap to fill
REALLY nice bull inside candle at a nice high. After a run up.. This would be VERY interesting short. I have zero issue losing 1R on this trade. However, I did mention in a Forbes article that big pharma is PROB going to be the best performing asset / sector From Oct 2022 to April 2023 (mid term election cycle)
The PEAD projected a Bullish outlook for $GILD after a Positive Under reaction following its earnings release placing the stock in drift A with an expected accuracy of 50%.
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes drugs in areas of unmet medical need such as human immunodeficiency virus (HIV) in the United States, Europe and internationally.
Revenue TTM 27.3B
Net Income TTM 6.2B
EBITDA TTM 12.5B
Debt/EBITDA TTM 2.5x
EBITDA Margin 45.9%
Net Margin 22.8%
Nice box testing the 250h.
The 50h and the 21h want to move on the right order after this pullback.
The previous high can be a target, while a breakdown has more targets.
![GILD: [GILD] - Short / Downside draw](https://s3.tradingview.com/9/9AyOswe3_mid.png "[GILD] - Short / Downside draw")
